Jubilant Pharmova

Jubilant Pharmova has appointed Daniel J. O’Connor as its new Chief Executive Officer, marking a pivotal leadership transition for the company as it accelerates its global pharmaceutical ambitions. O’Connor, a veteran executive with extensive experience in biotech, life sciences, and commercial strategy, is expected to drive the organization’s expansion across regulated markets while reinforcing its research and development capabilities. His appointment reflects Jubilant’s broader focus on operational strengthening, innovation-led growth, and long-term value creation for stakeholders.

Jubilant Pharmova has reported a strong financial performance for the first quarter of FY26, with profit after tax (PAT) rising 49% year-on-year to Rs. 103 crore. The pharmaceutical and life sciences company also posted an 8% increase in revenue, reaching Rs. 1,696 crore for the quarter. The growth was driven by improved performance across its key verticals, particularly in contract research and development services. This robust showing underscores the company's operational resilience and strategic focus on innovation-led growth.

In a significant move signaling portfolio realignment, the promoter entities of the Jubilant Group have divested partial stakes in three of their listed companies—Jubilant FoodWorks, Jubilant Ingrevia, and Jubilant Pharmova—via open market transactions amounting to Rs. 1,800.98 crore. The stake reduction alters promoter holdings notably across the group’s diversified interests, from food services to specialty chemicals and pharmaceuticals.

Jubilant Pharmova Ltd reported a sharp financial turnaround in the fourth quarter ended March 31, 2025, posting a consolidated net profit of Rs. 151.3 crore, reversing a loss of Rs. 61.8 crore from the same period last year. The company’s revenue and profitability saw robust growth both quarterly and annually, reflecting operational efficiency and strategic execution. For the full fiscal year, net profit surged to Rs. 836.3 crore—an exponential rise from Rs. 72.7 crore in FY24. With strong earnings and improved margins, the board has proposed a final dividend of Rs.